NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AKRO Stock Alerts $19.65 -1.15 (-5.53%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$19.59▼$21.4550-Day Range$18.93▼$31.1852-Week Range$11.25▼$58.38Volume567,401 shsAverage Volume702,395 shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$37.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Akero Therapeutics alerts: Email Address Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside91.9% Upside$37.71 Price TargetShort InterestBearish12.44% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.24Based on 23 Articles This WeekInsider TradingSelling Shares$3.42 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.93) to ($4.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector344th out of 925 stocksPharmaceutical Preparations Industry155th out of 430 stocks 3.4 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akero Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.44% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 5.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 1.8 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Akero Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,420,627.00 in company stock.Percentage Held by InsidersOnly 9.69% of the stock of Akero Therapeutics is held by insiders.Read more about Akero Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.93) to ($4.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akero Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesMay 3, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $100,750.00 in StockMay 12, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 12, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …May 10, 2024 | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 10, 2024 | businesswire.comAKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc.May 10, 2024 | prnewswire.comAKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.May 10, 2024 | investorplace.comAKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024May 10, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)May 12, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …May 10, 2024 | markets.businessinsider.comAkero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | msn.comAkero Therapeutics GAAP EPS of -$0.90 beats by $0.05May 10, 2024 | globenewswire.comAkero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comAkero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceMay 8, 2024 | prnewswire.comAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 7, 2024 | stockhouse.comAkero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit - Hagens BermanMay 7, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROMay 7, 2024 | prnewswire.comClass Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.May 7, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) InvestorsMay 6, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) InvestorsMay 6, 2024 | markets.businessinsider.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmMay 6, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) InvestorsMay 5, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 5, 2024 | stockhouse.comAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit!May 4, 2024 | americanbankingnews.comJonathan Young Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMay 3, 2024 | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 3, 2024 | markets.businessinsider.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmMay 3, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of InvestorsSee More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/12/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$37.71 High Stock Price Target$43.00 Low Stock Price Target$30.00 Potential Upside/Downside+91.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.59% Return on Assets-27.10% Debt Debt-to-Equity Ratio0.05 Current Ratio29.27 Quick Ratio29.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.61 per share Price / Book2.04Miscellaneous Outstanding Shares69,150,000Free Float62,450,000Market Cap$1.36 billion OptionableOptionable Beta-0.29 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.22MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $763.3kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Comp: $819.4kMr. William R. White J.D. (Age 50)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $768.4kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Comp: $754.8kMr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy Mr. John J. Schembri (Age 62)VP of Finance & Controller More ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXMorphicNASDAQ:MORFDynavax TechnologiesNASDAQ:DVAXXencorNASDAQ:XNCRDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 584,875 shares on 5/10/2024Ownership: 5.307%State Board of Administration of Florida Retirement SystemSold 5,190 shares on 5/9/2024Ownership: 0.014%ProShare Advisors LLCBought 2,945 shares on 5/8/2024Ownership: 0.022%Headlands Technologies LLCBought 3,024 shares on 5/8/2024Ownership: 0.006%Russell Investments Group Ltd.Bought 1,183 shares on 5/8/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $30.00 to $43.00. On average, they anticipate the company's stock price to reach $37.71 in the next year. This suggests a possible upside of 91.9% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2024? Akero Therapeutics' stock was trading at $23.35 at the beginning of the year. Since then, AKRO stock has decreased by 15.8% and is now trading at $19.65. View the best growth stocks for 2024 here. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.17. What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Tema Cardiovascular and Metabolics ETF (HRTS) and Simplify Health Care ETF (PINK) and What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.31%), Swiss National Bank (0.15%), Capstone Investment Advisors LLC (0.13%), BNP Paribas Financial Markets (0.09%), Entropy Technologies LP (0.08%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKRO) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.